Five Prime Therapeutics (FPRX) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
November 6, 2018 4:05 PM ESTInitiated Phase 3 FIGHT global registrational trial of bemarituzumab in gastric and gastroesophageal junction (GEJ) cancer Initiated FPA150 dosing in B7-H4 positive patients in Phase 1 exploratory cohort Opened enrollment for the FPT155 Phase 1 clinical trial in Australia Announced industry veteran David V. Smith will join as Executive Vice President and Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--... More
